is...Long
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I just love these figures and have to post them again. For CIs to work, you have to have plenty t cells in tumor micro-environment. But 80% of solid tumors have t cell depleted micro-enironment. That's why CIs lack of efficacy for cold tumors. For p3 trial, patients after SOC pic.twitter.com/RKR548eusJ
— d_stock (@d_stock07734) November 21, 2023
$NWBO - FTD data - missing 1st half Oct data. pic.twitter.com/SZ7YVPiejd
— Roberto (@rkawong66) November 20, 2023
DCVax improved median survival in BOTH new & recurrent #glioblastoma.
— rj (@sharpie510) November 21, 2023
☝️☝️
Like Immune Checkpoint Blockade, CAR T cell therapy also has failed to produce substantial benefits treating #GBM patients clinically.
The DCVax® Platform
💪💪$nwbo #dcvax
PDF: https://t.co/CKihqOItW5 pic.twitter.com/hexRoC5gI5
"Hoping it’s with the publisher by now"
Qué será, será
Whatever will be, will be
The future's not ours to see
Qué será, será
What will be, will be
https://tinyurl.com/bdekxpch
However, I am hopeful of being provided with the slide deck from Marnix Bosch's SNO presentation perhaps today ?
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 19, 2023
With $nwbo now awaiting the Judge's decision on MTD and potentially Citadel facing 'Discovery' perhaps it will be "the little engine that could" (as Les Goldman stated) that brings them down, certainly the US Government/Regulators either… pic.twitter.com/c86pqcB5Pr
$NWBO 🚀 pic.twitter.com/J9T7pFd06C
— autologous assassin 🇺🇸 🇺🇦 🇮🇱 (@flaskworks) November 18, 2023
Wow! I always thought the data from Dr. Bosch's presentation in June most likely from the patients receiving DCVax-L + Poly-ICLC. It seems like the patients who came from the p3 trial and received SOC. Cannot imagine what will be the number of T cells from the current combo. pic.twitter.com/Hl83XFPBso
— d_stock (@d_stock07734) November 18, 2023
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 19, 2023
"Stay tuned for more!" https://t.co/3tSQvgBZ1u
Thanks for posting the photos. I hope $NWBO will release some slides from Drs. Liau, Ashkan & Bosch poster after SNO2023, so we can see any new T cell clone & dynamic data after GBM patients are immunized with #DCVax-L. Immune response seems durable & increases after each shot. https://t.co/ylVYKLQphS
— ATLnsider (@ATLnsider) November 18, 2023
#dcvax #allsolidtumors $nwbo #gbm https://t.co/FNULHu4uXB
— Peter Davis (@peter_brit) November 18, 2023
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 18, 2023
November 2023 Insights from the UK and beyond Evaluating patient access to rare disease treatments
The call from the BioIndustry Association (BIA)’s Rare Disease Industry Group (RDIG) is informed by a new report by the BIA, with research… pic.twitter.com/hA9IT6r3NR
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 18, 2023
“Even though big pharma is sitting on big cash piles, and venture capitalists have billions in dry powder, there has been a reluctance to deploy the capital. Consequently, across the globe, biotech companies have struggled to raise new money.…
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 18, 2023
The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma
Posted Date: Aug 29;2023
The autologous tumor cell lysate-pulsed DC vaccine can target multiple antigens too. This personalized vaccination therapy also addresses…
Dr. Rathmell has been announced as the newly appointed Director of the National Cancer Institute, succeeding Dr. Bertagnolli, who moved on to lead the NIH. Dr. Rathmell, a distinguished physician-scientist with Stanford training and currently a faculty member at Vanderbilt, brings a wealth of expertise to the role. Her publication in May in Science Immunology highlighted her groundbreaking research in immunotherapy, particularly the use of STING-activating nanoparticles to enhance dendritic cells' ability to combat cancer. DCVax, anyone? Dr. Rathmell's appointment is a significant step forward for the field of immunotherapy, and I anticipate her leadership will be very good news to cancer patients. $NWBO investors, take note. To the Moon!!!
#dcvax #allsolidtumors $nwbo #gbm https://t.co/5sGBNrPTlq
— Peter Davis (@peter_brit) November 18, 2023
“We don't know the short positions…Because we have no way to have access to that information absent discovery,” Laura Posner said to the judge in the $NWBO case oral argument. Because the question is always going to be MOTIVE. The real argument has always been: were the market makers and their clients illegally spoofing the stock to protect their naked short position? If so, that spells motive for illegal action and they no longer will have any leg to stand on and have lost their case. Everyone wants to know… and she spelled it out clearly…
#dcvax #allsolidtumors $nwbo #gbm https://t.co/q1EIvql6vm
— Peter Davis (@peter_brit) November 18, 2023
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 18, 2023
Sentiment Stocks@sentimentstock
"Gotta love the judge's statement near the end, Judge Stein: “..if you have a GAZILLION... canceled orders & a GROSS imbalance in the sell side vs the buy side on the book ... it seems like you could infer… https://t.co/QljAkA9unG
@POTUS how is a cancer #moonshot going to work when the US can’t even get the most promising therapy for the cancer that killed your son GBM approved before the UK? $NWBO https://t.co/04ywJWjKYd
— Justin Keister MS DABR (@justinkeister5) November 17, 2023
In the last 18 hours 4,500,000 shares have become available to short with a current borrow fee rate of 25%, we could take a hit today perhaps?
https://fintel.io/ss/us/nwbo
It would not surprise me at all if he is involved. He is clearly well informed on the application process and current status.
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 17, 2023
Wonderful to see just how far word of $nwbo and DCVax® is spreading..https://t.co/a7ke9mdldo pic.twitter.com/GHLIU8xKYD
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 17, 2023
Excellent Cancer progress report.
'AACR Cancer progress report 2023'
"Therapeutic vaccines have also shown promise in the treatment of glioblastoma. In a phase III clinical trial, researchers added a vaccine based on dendritic cells (see… pic.twitter.com/td8CvTLNnH
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 17, 2023
Professor Keyoumars Ashkan:
"The next stage is to get the drug approved. In the UK, things are a little bit simpler and we have got a very efficient way of approval so that is good news and we are trying to get the drug approved, first in… pic.twitter.com/AxBMpzSLRL
Al Musella
@AlMusella
Hopefully something like dcvax could be used on any patient and can drastically improve that 8 month number with no side effects
#dcvax #allsolidtumors $nwbo #gbm https://t.co/LCYRTkkB8o
— Peter Davis (@peter_brit) November 17, 2023
hoffmann6383
@hoffmann6383
randomly one day we will see an opinion posted on pacer. it could be tomorrow or it could be 8 months from now. The public wont be given advance notice. The last Harrington MTD took 4 months for the judge to issue an opinion. I expect our decision to be quicker than that.
#dcvax #allsolidtumors $nwbo #gbm https://t.co/sobuaG3M6c
— Peter Davis (@peter_brit) November 17, 2023
Gregory Zivic, MD
@metacollectiveG
They’re not as powerful as you think. They understand they’ve lost this one and when the MAA is submitted the floodgates will open and the public will understand and the game is over
#dcvax #allsolidtumors $nwbo #gbm https://t.co/3JepNBwbHn
— Peter Davis (@peter_brit) November 17, 2023
There seems to be an ongoing criminal investigation into Failures to Deliver (FTD) of #AMC #GME and #Meme Stocks.
This is a FOIA request by a shareholder, which indicates the government’s inability to provide FTD records for OCTOBER 1-15th 2023 due to an ongoing investigation.
https://twitter.com/peter_brit/status/1725352266536796603
Wow... the first 20 pages detail $nwbo's catalogue of worldwide patents, I say again 20 pages! It is truly a fascinating insight and further indication of the company's potential. Applications to the four Regulators where the P3 trial took place is only the very beginning.…
— Peter Davis (@peter_brit) November 16, 2023
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 16, 2023
Interesting that Japan has been added to the list of Project Orbit's list of participating countries..
"In Japan, we have nine issued patents and three pending patent applications relating to our DCVax products, as well as manufacturing…
#FriendsAM23 policy papers focus on optimizing #clinical trials.
— Friends of Cancer Research (@CancerResrch) November 14, 2023
Maximizing Use of Data from Academic-Led Studieshttps://t.co/VG9QS6vN2r
Early Phase Trialshttps://t.co/G3GRIFEcQJ
Incorporating Pragmatic Trial Elementshttps://t.co/TxT3ubxR5i pic.twitter.com/NLMqARdPoC
Starting now! “Lunch Keynote — Overview of @US_FDA OCE Projects.” Moderated by : @realrickpazdur
— Friends of Cancer Research (@CancerResrch) November 14, 2023
highlighting @FDAOncology Project Community, Project Facilitate, Project ORBIS, Project Confirm, and Project Catalyst.https://t.co/HQIDuHbXs5#FriendsAM23 pic.twitter.com/XUP6CFajhR
Fresh off the press... PDMA (Japanese Regulatory Agency) is joining Project ORBIS
#dcvax #allsolidtumors $nwbo #gbm https://t.co/4h7N0mKuDn
— Peter Davis (@peter_brit) November 16, 2023
🌐Exciting updates from #ISPOREurope
— NICE (@NICEComms) November 14, 2023
This year features various NICE speakers covering a wide range of healthcare topics including:
💡 Real-world evidence
💻AI to support HTA
🔍and how environmental sustainability should be considered in HTA and guideline development. pic.twitter.com/prpzH4xvTN
#dcvax #allsolidtumors $nwbo #gbm
— Peter Davis (@peter_brit) November 16, 2023
Interesting White paper from Friends of Cancer Research:-
Incorporating Pragmatic Elements in Study Designs to Enhance Oncology Randomized Clinical Trialshttps://t.co/VwGPiljTws pic.twitter.com/V7prGDuWBO
Get the latest practice-changing advancements in #Glioblastoma management with experts @StevenBremMD & @BrainTumorDoc. Join @theABTA & @PeerView on Thursday, November 16th at 5:15 PM PST during #SNO2023! https://t.co/mraonUBM3p #BTSM #BrainTumor #MedEd #MedTwitter
— Mindy Freund, MSN, RN, CCRC (@Mindy_Freund) November 15, 2023